true

Shape the future of cervical cancer screening.

Identify HPV 31

Header Image

BD ONCLARITY™ HPV ASSAY IS THE ONLY FDA AND HEALTH CANADA APPROVED HPV TEST THAT INDIVIDUALLY IDENTIFIES HPV 31.

HPV 31 POSES A HIGHER RISK FOR CERVICAL PRECANCER AS COMPARED TO HPV 18.

The BD Onclarity™ HPV Assay with extended genotyping allows for a more precise, accurate way to measure a woman’s risk for developing cervical pre-cancer and cancer compared to an assay with partial genotyping.1,2,3 HPV 31 identification matters. Extended genotyping is critical.

APPROPRIATE AND TIMELY CLINICAL MANAGEMENT

A systematic review of 16 studies shows that HPV 31 poses a similar or higher risk for CIN3+ disease as compared to HPV 18, above the ASCCP’s 4% immediate risk of CIN3+ threshold for referral to colposcopy.4,5

 

ACCURATE RISK-STRATIFICATION

Most HPV tests report multiple genotypes in a single result, which can both artificially mask the true risk of CIN3+ disease - especially due to HPV 31 - and lead to a 1-year follow-up recommendation instead of an immediate colposcopy referal.5,6
 

Learn more about extended genotyping with the BD Onclarity™ HPV Assay

Additional resources

References

* ASCCP, American Society for Colposcopy and Cervical Pathology; CIN, Cervical Intraepithelial Neoplasia; HPV, human papillomavirus

1. Monsonego J et al. Gynecol Oncol. 2015;137(1):47-54.
2. Stoler MH et al. Am J Clin Pathol. 2019;151(4):433-42.
3. Salazar K et al. J Am Soc Cytopath. 2019;8:284-92.
4. Perkins RB et al. J Low Genit Tract Dis. 2020;24:102-31.
5. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1-13.
6. Drolet M et al. Lancet. 2019;394(10197):497-509.

BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.

true